Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Abbott, Alere Agree To Mediation For Troubled Merger

Executive Summary

Abbott announced plans to purchase Alere in January, but the merger has so far been delayed by, Alere alleges, Abbott's foot-dragging. Abbott, meanwhile, points to federal investigations that have delayed Alere’s financial filings.

You may also be interested in...



January Court Date Set for Abbott, Alere Merger

A hearing in Alere’s court case to force Abbott to complete the merger has been set for Jan. 27. The hearing will only be held if the companies can’t complete the merger by that date. Delaware Chancery Court has also adopted Abbott’s proposed schedule for merger activities.

J&J Buys Abbott's Ophthalmics Business For $4bn-Plus

The move to sell Abbott Medical Optics unit comes in the midst of a significant portfolio overhaul by Abbott. The deal will put J&J in the ophthalmic surgery business.

Alere Sues To Compel Completion Of Abbott Merger

Abbott's confidence in the planned $5.8b deal has declined since the acquisition was announced in January following disclosures of investigations into Alere's business practices. Alere hopes the suit will prod Abbott to speed its efforts to secure regulatory approvals for the merger.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT103814

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel